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Abstract
BACKGROUND—Neural tube defects (NTD)s, which occur when the neural tube fails to close 
during early gestation, are some of the most common birth defects worldwide. Alcohol is a known 
teratogen and has been shown to induce NTDs in animal studies, although most human studies 
have failed to corroborate these results. Using data from the National Birth Defects Prevention 
Study, associations between maternal reports of periconceptional (1 month prior through 2 months 
postconception) alcohol consumption and NTDs were examined.
METHODS—NTD cases and unaffected live born control infants, delivered from 1997 through 
2005, were included. Interview reports of alcohol consumption (quantity, frequency, variability, 
and type) were obtained from 1223 case mothers and 6807 control mothers. Adjusted odds ratios 
(aOR)s and 95% confidence intervals were estimated using multivariable logistic regression 
analysis.
RESULTS—For all NTDs combined, most aORs for any alcohol consumption, one or more 
binge episodes, and different type(s) of alcohol consumed were near unity or modestly reduced 
(≥0.7<aOR≤1.1) and were not statistically significant. Findings were similar for individual NTD 
subtypes.
CONCLUSIONS—These findings suggest no elevated association between maternal 
periconceptional alcohol consumption and NTDs. Underreporting of alcohol consumption, due to 
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negative social stigma associated with alcohol consumption during pregnancy, and limited reports 
for mothers with early pregnancy loss of a fetus with an NTD may have affected the estimated 
odds ratios. Future studies should aim to increase sample sizes for less prevalent subtypes, reduce 
exposure misclassification, and improve ascertainment of fetal deaths and elective terminations.
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INTRODUCTION
Neural tube defects (NTD)s are some of the most common birth defects worldwide. In the 
United States (US), more than 3000 NTD-affected pregnancies occur annually (Centers for 
Disease Control and Prevention, 2004). Survival of infants with NTDs varies by subtype. 
Anencephaly is invariably fatal, whereas children with spina bifida frequently experience 
severe disability (Date et al., 1993) and require continued medical treatment (Zurmohle et 
al., 1998). In 2003 dollars, Grosse et al. (2008) estimated the direct lifetime costs of spina 
bifida to be $560,000 per child. Randomized controlled trials showed that folic acid 
supplementation could prevent at least one-half of all NTDs (Medical Research Council, 
1991; Czeizel and Dudas, 1992), leading to mandatory folic acid fortification of enriched 
grains in the United States in 1998. Although NTD rates in the US decreased by an 
estimated 26% following folic acid fortification (Centers for Disease Control and 
Prevention, 2004), persistence of NTDs suggests presence of other risk factors or that such 
fortification is not sufficient (Cavalli and Copp, 2002).
Alcohol is a known teratogen, with effects that may be more pronounced during 
organogenesis (Yanaguita et al., 2008). A potential association between alcohol 
consumption and NTDs was first described in a case series more than 25 years ago 
(Friedman, 1982); however, the biological mechanisms by which alcohol impacts neural 
tube development are not well understood. Animal models suggest that prenatal alcohol 
exposure in early development can lead to excessive neural crest cell death (Bannigan and 
Burke, 1982), as well as contribute to folic acid deficiency via increased excretion of folic 
acid by the kidneys (McMartin, 1984; Muldoon and McMartin, 1994).
Published human studies of maternal alcohol consumption and NTDs have produced results 
inconsistent with animal studies. Two studies (Mills and Graubard, 1987; McDonald et al., 
1992), which did not control for folic acid intake, found no association between alcohol 
consumption during the first trimester of pregnancy and NTDs. Among studies that 
controlled for folic acid supplementation, three reported no association with any level of 
alcohol consumption examined (Shaw et al., 1996, 2002; Suarez et al., 2008), and one 
reported a significantly positive association [OR: 2.1; 95% confidence interval (CI): 1.1, 
4.0] with alcohol consumption of least once per week (Grewal et al., 2008).
Important limitations of previous epidemiologic studies were the lack of comprehensive 
analyses of important covariables and investigation of associations for NTD subtypes. 
Specifically, no study examined associations by type of alcohol consumed. Folate levels are 
thought to vary by type of alcohol. Larroque et al. (1992) reported a positive correlation 
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between red cell folate levels and alcohol consumption in pregnant women, most of whom 
consumed beer. Stark et al. (2005) found similar results in pregnant African American 
women, with a non-significant, but positive association between beer consumption and 
plasma 5-MTHFA (the most common folate metabolite) and a significant negative 
association between wine cooler consumption and plasma 5-MTHFA. Also, due to limited 
data and/or small sample sizes, few previous studies were able to evaluate relevant 
covariables, including those known to be associated with NTDs (e.g., diabetes, exposure to 
folate antagonists) (Lammer et al., 1987; Becerra et al., 1990). Additionally, only two 
studies (Mills and Graubard, 1987; Grewal et al., 2008) examined NTD subtypes. This is 
important because of the potential developmental and etiologic heterogeneity in NTD 
development (Reviewed by Mitchell, 2005). The inability to stratify by NTD subtype could 
dilute reported associations due to this underlying heterogeneity.
Data from the National Birth Defects Prevention Study (NBDPS), an ongoing, population-
based, multisite case–control study, were used to investigate the association between 
maternal reports of alcohol consumption and NTD subtype. The NBDPS sample is 
sufficiently large to address existing limitations in the alcohol-NTD literature such as 
analysis by select subtypes, stratification by type of alcohol consumed, and examination of 
important covariables.
MATERIALS AND METHODS
The NBDPS was designed to investigate genetic and non-inherited risk factors for over 30 
major, structural birth defects including NTD subtypes (British Pediatric Association, 
1979]), anencephaly and craniorachischisis (740.000–702.100), spina bifida (741.000–
741.990), encephalocele, cranial meningocele, encephalomyelocele, and other rare subtypes 
(742.000–742.990). Case definitions for each eligible defect required confirmatory 
diagnostic procedures. The NBDPS excluded cases with known single gene or chromosomal 
etiologies. Clinical geneticists at each NBDPS site reviewed reports from medical records to 
determine case eligibility. A brief description of NBDPS methods is provided below; 
additional detail is reported elsewhere (Yoon et al., 2001; Rasmussen et al., 2001, 2003). 
Each site obtained institutional review board approval for the NBDPS and all participants 
provided informed consent.
Data included in this report were collected at 10 sites (Arkansas, California, Iowa, 
Massachusetts, New Jersey, New York, North Carolina, Texas, Utah, and metropolitan 
Atlanta), which cover an annual birth population of 482,000, or about 10% of births 
nationally (Yoon et al., 2001). For this analysis, eligible NTD cases were live births (all 
sites), fetal deaths at 20 weeks or greater gestation (six sites), and elective terminations (five 
sites) with estimated dates of delivery (EDD)s from October 1, 1997 to December 31, 2005 
and diagnosed with at least one NTD subtype (anencephaly, craniorachischisis, spina bifida, 
encephalocele, cranial meningocele, or encephalomyelocele). NTD cases were further 
classified as isolated (no additional major defects) or multiple (more than one major 
unrelated defect) phenotypes. Eligible control infants were live births without a structural 
birth defect delivered during the same time period and randomly selected using birth 
certificates or hospital records from the same regions as the NTD cases.
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Participating mothers of eligible NTD cases and control infants completed the NBDPS 
interview no earlier than 6 weeks and no later than 24 months following the EDDs. The 
median time between the EDDs and the completed interviews was 9.5 months for case and 
8.9 months for control mothers. The NBDPS interview asked about maternal exposures, 
including infectious, chemical, physical, nutritional, and behavioral factors. For this study, 
the periconceptional period included the month before conception (B1) and the two months 
postconception (P1, P2). Including exposure reported in B1 allowed for analysis of mothers 
with unrecognized pregnancies who might have extended pre-pregnancy exposure patterns 
into P1 or later. The months, P1 and P2, encompass the relevant gestational period for 
development of NTDs.
Alcohol Consumption
The NBDPS interview collected data on quantity, frequency, and variability of alcohol 
consumption and on type(s) of alcohol consumed. Maternal periconceptional alcohol 
consumption was assessed using a previously developed approach (for details see Romitti et 
al., 2007). Mothers who reported consumption of alcohol during the periconceptional period 
were queried about the month(s) during which they drank (yes/no), the average number of 
drinking days per month (frequency), the average number of drinks per drinking day 
(quantity), the maximum number of drinks on one occasion per drinking month (variability), 
and type(s) of alcohol consumed (beer, wine, and/or distilled spirits).
Mothers were classified as exposed if they reported drinking alcohol during one or more 
periconceptional months. Maternal reports were excluded from analyses if, for any 
pregnancy month or trimester, alcohol consumption (yes/no) was missing or unknown or if 
reports of average drinking for any month were greater than 150 drinks. Alcohol 
consumption was also categorized by quantity-frequency reported. The average number of 
drinks per each drinking month was calculated by multiplying the reported average number 
of drinking days per month by the reported average number of drinks per drinking day for 
that month. A periconceptional average number of drinks per month (total average number 
of drinks per month divided by the number of months drank) and maximum average number 
of drinks per month (highest reported average number of drinks per month) were calculated 
for each mother. Using a 30-day month, four categories of consumption were used to 
classify the periconceptional average number of drinks per month and maximum average 
number of drinks per month: monthly to weekly (1–4 drinks per month); weekly to every 
other day (5–15 drinks per month); every other day to daily (16–30 drinks per month); and 
daily with more than one drink per day (>30 drinks per month). Binge drinking, measured 
using both sex-neutral (Naimi et al., 2003) and sex-specific (Wechsler et al., 1995) norms, 
was also categorized. Sex-neutral norms included five or more drinks per day on average, on 
one occasion, or both, whereas sex-specific norms for females included four or more drinks 
per day on average, on one occasion, or both. Case and control mothers were classified into 
one of three categories: no consumption, consumption without binge drinking, or at least one 
binge drinking episode. Finally, mothers were classified by type(s) of alcohol consumed, 
including beer only, beer plus other alcohol type (wine and/or distilled spirits), or other 
alcohol type only.
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Covariables
Covariables evaluated included maternal age at delivery (<21, 21–25, 26–30, 31–35, and 
>35), race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, Other), education 
(<12 years, 12 years, 13–15 years, 16 or more years), gravidity (0, 1, 2, 3, or more), pre-
pregnancy body–mass index (<18.5, 18.5–24.9, 25–29.9, ≥30), periconceptional smoking 
(yes/no), and NBDPS site. Additionally, dietary folate equivalent intake (<600 μg, ≥600 μg) 
and periconceptional use of folic-acid-containing supplements (yes/no) were examined. 
Dietary folate intake was assessed using responses to the Willet Food Frequency 
questionnaire (Willett et al., 1985, 1987) adapted for the NBDPS interview and measured 
food intake during the one year before conception and from reports of breakfast cereals 
consumed during P1 and P2. Dietary folate equivalents [DFE]s were estimated using the 
reported food frequencies, the standardized serving size on which a question item was based, 
and the United States Department of Agriculture National Standard Reference 16-1 (United 
States Department of Agriculture, 2004). Also, the NBDPS interview queried mothers 
regarding their intake of vitamins and supplements for a period of 3 months before 
conception through delivery. For each supplement reported, mothers were asked to provide 
start and stop dates (or if dates were unknown, duration of use) and frequency of intake. 
Each supplement was assessed to determine whether or not it contained folic acid. Eligible 
mothers were classified into two groups, those who took folic-acid-containing supplements 
during the periconceptional period and those who did not.
Statistical Analysis
Analyses were conducted using SAS software, version 9.2 (SAS Institute Inc, 2007). 
Descriptive analyses of NTD case and maternal characteristics were conducted by NTD 
subtype and compared to control infants and mothers using chi-square tests. Crude odds 
ratios (OR)s and 95% CIs were estimated to examine associations between any maternal 
periconceptional alcohol consumption, average and maximum average drinks per month, 
binge episodes, and alcohol type and all NTD cases combined. Results from descriptive 
analyses were used to construct the most parsimonious multivariable logistic regression 
models to predict NTDs using backward selection approaches. Covariables included in the 
preliminary model were those which, based on the descriptive analysis, were associated (p < 
0.20) with any alcohol consumption (yes/no) and/or NTD outcome; maternal age, BMI, and 
dietary food folate were entered as continuous variables. Backward selection was used to 
exclude covariables from the preliminary model beginning with the least statistically 
significant covariable (highest p-value) based on the Wald chi-square statistic. As each 
covariable was removed, the fit of the full model was compared to the reduced model fit 
using the log-likelihood ratio (LLR) test. Covariables for which the LLR was significant (p 
< 0.05), were re-entered into the model. Also, regardless of LLR values, covariables for 
which exclusion from the model resulted in a change in parameter estimate of an alcohol 
exposure variable by greater than 20% were reentered in the model. Based on the final 
multivariable logistic model, adjusted odds ratios (aORs) were estimated to characterize the 
association between all NTD cases combined and any periconceptional alcohol 
consumption, quantity-frequency of consumption, binge episodes, and type of alcohol 
consumed. In addition, aORs for maximum average monthly drinks and binge drinking were 
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stratified by type of alcohol, folic acid consumption, pregnancy intendedness (planned 
versus unplanned pregnancy) and family history of a NTD; aORs for type of alcohol were 
stratified by folic acid consumption. Finally, all analyses were conducted restricting infants 
to those sites who collected information on live births, fetal deaths, and elective terminations 
(five sites) and restricted to mothers exposed in P1 with/without exposure in P2 only. When 
numbers were sufficient, these subanalyses were also conducted by NTD subtype and 
phenotype.
RESULTS
Interview data were collected from mothers of 1223 (68% of eligible) NTD cases and 6807 
(66% of eligible) control infants. Of these, 56 case and 204 control mother interviews were 
excluded due to: incomplete interviews (case = 17; control = 104); maternal diagnosis of 
type 1 or type 2 diabetes before or during the index pregnancy (case = 18; control = 42); and 
maternal periconceptional exposure to known folic acid antagonists (case = 21; control = 
58). To improve homogeneity of NTD subtype groups, maternal interviews for an additional 
seven NTD cases were excluded due to diagnosis of multiple NTD subtypes for each case. 
Among the 1160 NTD cases included in the analyses, 328 were diagnosed with anencephaly 
or craniorachischisis, 703 with spina bifida, and 129 with another rare subtype.
Compared to control mothers, case mothers (all NTDs combined) were significantly more 
likely to be Hispanic, less educated, and to differ in proportions by site (Table 1). 
Anencephaly cases were more likely to be female and preterm (<37 weeks gestation) 
compared to control infants. Mothers of anencephaly cases were less likely to have reported 
periconceptional smoking, whereas those of spina bifida cases tended to be younger and 
have a pre-pregnancy body–mass index of 30 or more. Mothers of spina bifida and 
anencephaly cases were each more likely to have had four or more pregnancies than control 
mothers. Case and control mothers did not differ in use of folic-acid-containing supplements 
or food folate consumption.
Thirty percent of case mothers and approximately 36% of control mothers reported 
periconceptional alcohol consumption (Table 2); pattern of use was similar between the two 
groups. Case mothers were more likely to report consumption of beer only, whereas control 
mothers were more likely to report consumption of other alcohol types. Duration and type of 
alcohol consumed were similar among mothers of infants of each NTD subtype. When 
stratified by 6-month intervals between EDD and time to interview (1–6 months, 7–12 
months, 13–18 months, and 19–24 months), consumption frequency between case and 
control mothers was similar as the time to interview increased; however, in control mothers, 
the frequency was somewhat lower for those with the shortest (1–6 months) and longest 
(18–24 months) intervals, 38 and 25%, respectively (data not shown).
After adjustment for maternal race/ethnicity, education, pre-pregnancy body–mass index, 
periconceptional smoking, and NBDPS site, any maternal periconceptional alcohol 
consumption was not associated with all NTD cases combined. Similarly, when compared to 
no periconceptional alcohol consumption, no associations were found for maximum average 
monthly drinks (Table 3) or sex-specific binge episodes (Table 4) for all NTD cases 
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combined. Also, no patterns were seen with increasing number of maximum average drinks. 
Results for binge episodes did not appreciably change when using sex-neutral norms (data 
not shown). Adjusted analyses for all NTD cases combined for reported type(s) of alcohol 
consumed also did not show a pattern of elevated odds ratios (Table 5). Results were similar 
for each subtype and for isolated NTD cases only.
The aORs for maximum number of monthly drinks and one or more binge episodes did not 
change appreciably when stratified by type of alcohol consumed, folic acid supplementation, 
pregnancy intendedness, or family history of an NTD; however, odds were significantly 
elevated in mothers of spina bifida cases who reported no folic acid consumption and beer 
consumption only compared to no alcohol consumption (aOR = 1.8, CI = 1.1–2.9). Further, 
sub-analyses restricted to the five sites which ascertained live births, fetal deaths (≥20 weeks 
gestation), and elective terminations produced little change in the aORs (data not shown). 
Sub-analyses restricted to mothers exposed in P1 with/without exposure in P2 only produced 
similar results.
DISCUSSION
The current study included nearly twice as many NTD cases as the largest prior study (Shaw 
et al., 1996) and improved upon exposure classification, allowing for sub-analyses by 
alcohol type. Even with these design enhancements, the current study did not identify a 
pattern of elevated associations between any maternal periconceptional alcohol consumption 
and all NTD cases combined or any NTD subtype. It also did not identify elevated 
associations for reported maximum average monthly drinks for all NTD cases combined and 
most NTD subtypes. Additionally, little variation in the magnitude of associations by type(s) 
of alcohol consumed was found. Despite the relatively large sample size, the relatively low 
number of NTDs, particularly in subtype analyses, resulted in imprecise estimates.
The analyses of maternal periconceptional alcohol consumption and NTDs used data from 
one of the largest US population-based, case–control studies of birth defects. With our 
sample size and a 36% rate of periconceptional alcohol consumption in controls, a priori 
power calculations showed that our minimum detectable odds ratio for an association 
between any periconceptional alcohol consumption (yes/no) and NTDs combined was 1.15. 
The results were similar to the six previously published studies identified that examined the 
association between maternal alcohol consumption and NTDs (Mills and Graubard, 1987; 
McDonald et al., 1992; Shaw et al., 1996, 2002; Suarez et al., 2008). Among these studies, 
only one study (Grewal et al., 2008) reported a significant, positive association (with ≥1 
drink per week). Notably, this positive association was found only in adjusted analyses. No 
prior study had examined the association between alcohol exposure and NTDs by type of 
alcohol consumed, although prior work suggested that beer consumption increased red cell 
folate and plasma 5-MTHFA (Larroque et al., 1992; Stark et al. 2005). Because of the well-
established role of folate in preventing NTDs (Medical Research Council, 1991; Czeizel and 
Dudas, 1992), this study examined the association between alcohol exposure and NTDs by 
alcohol type, but found no variation in risk.
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The current study improved upon prior studies in several ways. The primary strength of this 
analysis was the large, population-based, geographically and ethnically diverse sample. The 
use of a population-based sample reduced the risk of selection bias. Comparison of selected 
maternal characteristics of controls versus all live births at each site has shown that NBDPS 
participants tend to be similar to all live births (Cogswell et al., 2009). Also, all NTD cases 
were reviewed and verified by clinical geneticists, decreasing the risk of case 
misclassification. In addition, the large sample size allowed for stratification by NTD 
subtype, which is important due to the potential heterogeneity of risk factors among 
subtypes.
Exposure data collection was conducted through detailed maternal interview reports using a 
structured questionnaire. Detailed data allowed assessment of alcohol consumption by 
quantity, frequency, and variability, as well as alcohol type, which had not previously been 
investigated. With the use of retrospective reports, the potential for differential recall existed 
between case and control mothers, although Verkerk et al. (1994) reported no significant 
differences in prospective and retrospective reports of alcohol between case and control 
mothers. Also, in the current study, the frequency of reported periconceptional alcohol 
consumption for case and control mothers stratified by 6-month intervals were similar as the 
time to interview increased.
Despite improvements upon prior similar studies, the lack of a positive association may be 
explained in several ways. There may in fact be no positive association between maternal 
periconceptional alcohol exposure and NTDs, although this conclusion is inconsistent with 
previous animal studies (Graham and Ferm, 1985; Hunter et al., 1994; Chen et al., 2005; 
Yanaguita et al., 2008). As mentioned, the biological mechanisms by which alcohol impacts 
neural tube development are not well understood. Animal models suggest that prenatal 
alcohol exposure in early development leads to excessive cell death (Bannigan and Burke, 
1982), particularly among premigratory neural crest cells (Kotch and Sulik, 1992). This may 
result in too few cells for fusion of the neural folds (Copp et al., 2003; Greene and Kopp, 
2006). Animal models also suggest that alcohol exposure may play an indirect role in NTD 
development (Yanaguita et al., 2008) by contributing to folic acid deficiency via increased 
excretion of folic acid by the kidneys (McMartin, 1984; Muldoon and McMartin, 1994).
The discrepant findings between animal and human studies may be explained, in part, by 
methodological limitations of human studies. For example, misclassification of timing and 
dose of alcohol could bias results. In the NBDPS, mothers were not queried regarding the 
precise volume of alcohol drinks consumed, rather general volumes (one can of beer, one 
glass of wine, and one shot of liquor) were assumed. Varying alcohol concentrations 
between types of alcohol could have decreased differences in odds ratios by type(s) of 
alcohol consumed. Also, alcohol consumption and dose were self-reported retrospectively, 
and may have been under-reported due to the negative social stigma associated with alcohol 
consumption during pregnancy, especially when the health of the infant is known. It is 
unclear if this would result in non-differential or differential exposure misclassification and 
the impact on the magnitude and direction of the odds ratios is uncertain. An alternative 
explanation for the discrepant results with animal studies is that the lack of association seen 
here may be due to selective early pregnancy loss of fetuses with NTDs creating an 
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ascertainment/survival bias; a large proportion of pregnancies affected by NTDs result in 
early fetal deaths (e.g., <20 weeks) (Centers for Disease Control and Prevention, 2004). 
Such cases are difficult to include in retrospective case–control studies, as the pregnancy 
may not have been recognized or the defect may not have been identified at the time of loss. 
Alcohol consumption has been associated with early pregnancy loss (Sokol, 1980; 
Henriksen et al., 2004) and could increase the likelihood of such study bias (Khoury et al., 
1992).
In summary, the association between periconceptional alcohol consumption and NTDs was 
investigated using a large, case–control study. Results suggested no pattern of increasing 
odds per amount of alcohol consumed. Although these findings corroborate the null findings 
of previous studies, and efforts were made to improve study design, these results should be 
interpreted cautiously, as a few limitations exist. Future studies should aim to increase 
sample sizes for less prevalent subtypes, reduce exposure misclassification, and improve 
ascertainment of fetal deaths and elective terminations.
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